Look back at pharma news in the week to April 16, 2021
By Barbara Obstoj-Cardwell. Editor
Among last week’s notable news, Biogen and Sage Therapeutics presented new data on their essential tremor candidate SAGE-324, which raised questions on tolerability. Roche and Regeneron released Phase III data confirming the efficacy of their COVID-19 antibody cocktail – casirivimab and imdevimab – for the treatment of this infection. In another disappointment in the COVID-19 space, Merck & Co said it is discontinuing development of MK-7110 as a treatment for hospitalized patients. In the latest investigation of thromboembolic events linked to novel coronavirus vaccines, the US Food and Drug Administration has launched a review of Johnson & Johnson’s COVID-19 candidate. On the deal making front, the UK’s C4X Discovery signed an agreement with French pharma major Sanofi on an oral pre-clinical interleukin (IL)-17A inhibitor program.
Sage’s technical tremor win fails to move
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze